EOM Pharmaceutical Holdings Inc. (IMUC)

[9HikeDiscGolf]

ImmunoCellular Therapeutics Successfully Transfers T Cell Receptor Genetic Material into Human Stem Cells
MT NEWSWIRES 5:17 AM ET 4/12/2018

07:17 AM EDT, 04/12/2018 (MT Newswires) -- ImmunoCellular Therapeutics(IMUC/WS) , a Los Angeles-based clinical-stage company, said early Thursday it has been able to verify a successful transfer of selected T cell receptor genetic material into human hematopoietic stem cells.

Successful completion of this phase of work enables the company to begin preclinical testing in animals, which, if successful, could allow ImmunoCellular's Stem-to-T-Cell technology to advance into human clinical testing.

ImmunoCellular's Stem-to-T-Cell technology is designed to stimulate the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects.

CEO Anthony J. Gringeri, PhD said, "We are also continuing to explore potential collaborations for our clinical programs and other strategic alternatives for our company."

Price: 0.235, Change: +0.001, Percent Change: +0.256

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

©http://www.mtnewswires.com Copyright © 2018 MT Newswires. All rights reserved.